GV, Mass General Brigham Ventures and existing investor Lonza helped Affinia Therapeutics raise $110m that will fund the progress of its gene therapy candidates.
US-based gene therapy developer Affinia Therapeutics completed a $110m series B round on Monday featuring chemicals producer Lonza, internet and technology group Alphabet and healthcare provider Mass General Brigham.
EcoR1 Capital and Farallon Capital Management co-led the round, which included investment and financial services group Fidelity’s F-Prime Capital subsidiary, while Alphabet and Mass General Brigham took part through GV and Mass General Brigham Ventures respectively.
Avidity Partners, Casdin Capital, Octagon Capital, Perceptive Advisors, RA Capital Management, TCG Crossover, Woodline Partners,…
